公开(公告)号：US20230085847A1

公开(公告)日：2023-03-23

申请号：US17933133

申请日：2022-09-19

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.

公开(公告)号：US20200369765A1

公开(公告)日：2020-11-26

申请号：US16629588

申请日：2018-07-09

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN ,  LAURENT GAUTHIER

IPC: C07K16/28

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US20240124579A1

公开(公告)日：2024-04-18

申请号：US18396776

申请日：2023-12-27

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  SIMON KOLLNBERGER ,  BENJAMIN ROSSI ,  HÉLÈNE SICARD ,  CARINE PATUREL ,  STÉPHANIE CORNEN ,  STÉPHANIE ZERBIB

IPC: C07K16/28 ,  G01N33/569

CPC classification number: C07K16/2803 ,  G01N33/56966 ,  G01N33/56972 ,  A61K2039/505 ,  G01N2800/7095

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

公开(公告)号：US20200369764A1

公开(公告)日：2020-11-26

申请号：US16629585

申请日：2018-07-09

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.

公开(公告)号：US20170306014A1

公开(公告)日：2017-10-26

申请号：US15509859

申请日：2015-09-09

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395

CPC classification number: C07K16/2803 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76

Abstract: This invention relates to agents that bind multiple Siglecs, including antibodies that neutralize the inhibitory activity of multiple Siglec-7 and Siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US20150232556A1

公开(公告)日：2015-08-20

申请号：US14662349

申请日：2015-03-19

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  SIMON KOLLNBERGER ,  BENJAMIN ROSSI ,  HÉLÈNE SICARD ,  CARINE PATUREL ,  STÉPHANIE CORNEN ,  STÉPHANIE ZERBIB

IPC: C07K16/28 ,  G01N33/569

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

Abstract translation: 本发明涉及使用特异性结合KIR3DL2的抗体（例如单克隆抗体），抗体片段及其衍生物来治疗癌症和炎性疾病的方法。 本发明还涉及抗体，产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 含有该组合物的药物组合物。